CureVac (NASDAQ:CVAC – Get Free Report) and OSR (NASDAQ:OSRH – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Volatility & Risk
CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Valuation & Earnings
This table compares CureVac and OSR”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
| OSR | $1.81 million | 3.69 | -$27.06 million | ($0.37) | -0.51 |
CureVac has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
17.3% of CureVac shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 2.1% of CureVac shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares CureVac and OSR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| OSR | -593.15% | -8.36% | -6.24% |
Analyst Recommendations
This is a summary of recent ratings and target prices for CureVac and OSR, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
Summary
CureVac beats OSR on 7 of the 11 factors compared between the two stocks.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
